Latest research on Tenofovir

Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. [Wikipedia] In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate.

Tenofovir side effects

Moreover, Tenofovir caused similar changes in primary vaginal epithelial cells cultured from several healthy women. [source]
We did not find evidence that Tenofovir directly causes inflammation, which is in keeping with our prior report that rectal Tenofovir gel did not cause overt histological inflammation or increased mRNA/protein levels of a select panel of pro-inflammatory cytokines (McGowan et al., 2013). [source]
In concert, these changes suggest that Tenofovir creates a state of potential hyper-responsiveness to external inflammatory stimuli but does not itself cause inflammation. [source]
In our study, just 1 week of daily Tenofovir 1% gel application lowered transcription of mitochondrial ATP6 by sixfold and caused visible ultrastructural mitochondrial changes. [source]
A number of changes in rectal biopsies and primary vaginal epithelial cells also suggested that Tenofovir can cause increased epithelial proliferation. [source]